January 30, 2019
GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL)
Read More
January 30, 2019
Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)
Read More
January 30, 2019
“Retrospective Study to Identify Clinical Factors Related to a High Benefit of Axitinib in mRCC”
Read More
January 30, 2019
“Retrospective Study to Identify Clinical Factors Related to a High Benefit of Axitinib in mRCC”
Read More
January 30, 2019
A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)
Read More
January 30, 2019
A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following Unsuccessful Treatment With Sunitinib in Patients With Advanced Renal Cell Cancer.
Read More
January 30, 2019
A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following Unsuccessful Treatment With Sunitinib in Patients With Advanced Renal Cell Cancer.
Read More
January 30, 2019
Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients
Read More
January 30, 2019
Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma
Read More
January 30, 2019
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
Read More
January 30, 2019
Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell Carcinoma
Read More
January 30, 2019
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
Read More
Load More
X